After 2 positive trials, low-dose colchicine’ got the FDA nod for CV reduction but then the CLEAR SYNERGY trial found no ...

Expectations for Novartis' canakinumab as an oncology therapy were already fading fast, and have now been nixed after a third phase 3 trial in non-small cell lung cancer (NSCLC) failed to meet its ...

Novartis kicked off its R&D update in London this morning by pledging to bring at least 10 drugs into pivotal trials in 2020 and 2021 from a mid-stage pipeline packed with 60 projects. All told ...

Generalized pustular psoriasis is a very rare and extreme form of psoriasis. It’s characterized by reoccurring flare-ups that cause pus-filled bumps and red or discolored skin over a large part ...

We will be in touch to let you know what type of appointment you will be having. For FEVER PATIENTS who receive treatments at the Centre, such as Canakinumab, Anakinra and Tocilizumab, they will ...

Longer acting IL-1 blockers including rilonacept and canakinumab that allow weekly or monthly subcutaneous dosing are available and approved for treatment of the milder forms of CAPS; however, they ...

canakinumab, guselkumab, ixekizumab, risankizumab, sarilumab, secukinumab, tocilizumab, ustekinumab Increased risk of serious infections, increased risk of some cancers DMARD = disease-modifying ...

These findings may lead to a new understanding of the use of colchicine in CVD treatment. The monoclonal antibody canakinumab can neutralize IL-1β directly. Canakinumab’s Canakinumab Anti-Inflammatory ...

These studies evaluated the role of Canakinumab (a fully human anti-IL1β monoclonal antibody) (NCT02888080) (281); and RCI (NCT03320070) (282) in patients with pulmonary sarcoidosis. Canakinumab is a ...